Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis (EXEL), an oncology-focused biotechnology company, is highlighted as a strong momentum stock, holding a Zacks Rank #2 (Buy) and top-tier 'A' ratings for both its VGM and Momentum Style Scores. The company's shares have gained 2.3% over the past four weeks, underpinned by recent positive analyst revisions; 10 analysts have increased their fiscal 2025 earnings estimates, raising the Zacks Consensus Estimate to $2.61 per share, and the company boasts an average earnings surprise of 48.6%. This robust performance and positive outlook suggest EXEL warrants consideration for investors' short lists.

Analysis

Exelixis (EXEL) is demonstrating significant positive momentum, underpinned by favorable analyst sentiment and strong quantitative ratings. The stock holds a Zacks Rank #2 (Buy) and top-tier 'A' scores for both its overall VGM (Value, Growth, Momentum) and specific Momentum metrics. This positive assessment is directly correlated with a wave of upward earnings estimate revisions for fiscal 2025, where 10 analysts have raised their forecasts over the past 60 days. Consequently, the consensus earnings per share estimate has increased by $0.30 to $2.61. The bullish outlook is further supported by the stock's recent performance, with a 2.3% gain over the past four weeks, and a historical track record of substantially exceeding expectations, evidenced by an average earnings surprise of 48.6%.

Key Decisions for Investors

• Investors with a momentum-driven strategy should consider EXEL, as the combination of positive price action, an 'A' momentum score, and upward earnings revisions aligns with the core tenets of this approach.
• The broad-based positive analyst sentiment, reflected in 10 upward revisions for fiscal 2025 earnings, suggests a strong fundamental outlook that may warrant establishing or adding to a long position.
• It is crucial to monitor upcoming earnings reports and analyst estimate trends, as the current bullish thesis is heavily dependent on the continuation of positive earnings surprises and forecast revisions.